Abeona therapeutics® announces abo-503 gene therapy for x-linked retinoschisis (xlrs) selected by fda for rare disease endpoint advancement (rdea) pilot program

Rdea pilot program provides sponsors enhanced communication and collaboration with fda to accelerate development of rare disease therapies rdea pilot program provides sponsors enhanced communication and collaboration with fda to accelerate development of rare disease therapies
ABEO Ratings Summary
ABEO Quant Ranking